Securities Exchange Commission SEC Washington DC

Bextra and Celebrex Securities Fraud

Investors alleged that drugmaker Pfizer violated federal securities laws by making false, misleading or incomplete statements regarding the cardiovascular risks of Celebrex and Bextra. Seeger Weiss helped secure a $486 million settlement on behalf of the investors.


Prior results do not guarantee or predict a similar outcome in any future matter.

Our Role

Seeger Weiss attorneys played a key role in this case, helping negotiate an efficient and positive settlement for investor plaintiffs. Partner Dave Buchanan developed a slate of experts to overcome Pfizer’s early science challenges to the case. Founding partner Chris Seeger led the plaintiff’s presentation and examinations during the seven-day Daubert hearing.

Following pre-trial motion practice and ensuing appeals, Pfizer settled the case, resulting in a $486 million cash settlement fund for the class of aggrieved investors.